More recent work has demonstrated that EGFR inhibitors are synergistic with trastuzumab in models of HER2+ breast cancer [14–16], again suggesting that EGFR is important as an alternative pathway when HER2 is inhibited. This evidence concerns the gene ERBB2 and breast carcinoma.